Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 59-63 , February 2003

Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer: Abstracted from: Douillard J, Hoff P, Skillings J et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2002; 20: 3605–16.

References 

  1. Greenlee RT, Murray T, Bolden S, et al.  Cancer Statistics 2000. CA Cancer J. Clin. 2000;50:7–33
  2. Ragnhammer P, Hafström L, Nygren P, et al.  A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40:283–308
  3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903
  4. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308
  5. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors: J Clin Oncol 1998; 16: 3537–3541
  6. Douillard JY, Cunningham D, Roth AD, et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041–1047
  7. Saltz LB, Cox JV, Blanke C, et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000;343:905–914
  8. Sargent D, Niedzwiecki D, O’Connell M, et al.  Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N. Engl. J. Med. 2001;345:144–145
  9. Mayer R. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it’s all the same. J. Clin. Oncol. 2001;19:4093–4096
  10. Levin J, Schilsky R, Burris H, et al. North American phase III study of oral eniluracil (EU) plus oral 5-fuorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20: (Abstract 523)
  11. van Custen E, Sorensen J, Cassidy J, et al. International phase III study of oral eniluracil (EU) plus 5-fuorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001; 20: (Abstract 522)
  12. Hoff PM, Ansari R, Batis G, et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 2001;19:2282–2292
  13. Cutsem E, Twelves C, Cassidy J, et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001;19:4097–4106
  14. Hoff PM. Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. Ann. Oncol. 2000;11(Suppl. 4):60; (Abstract 263)
  15. Rustum YM, Maestrick A, Cao S, et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 1997;15:389–400
  16. Wellington K, Goa KR. Oral tegafur/uracil. Drugs Aging. 2001;18:935–950
  17. Pazdur R, Lassere Y, Rhodes V, et al.  Phase II study of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal cancer. J. Clin. Oncol. 1994;12:2296–2300
  18. Gonzales-Baron M, Feliu J, de la Gandara I, et al.  Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer: a phase II study. Eur. J. Cancer. 1995;31:2215–2219
  19. Feliu J, Gonzales-Baron M, Espinosa E, et al.  Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal cancer. Cancer. 1997;79:1884–1889
  20. Saltz LB, Leichman CG, Young CW, et al.  A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer. 1995;75:782–785
  21. Diaz-Rubio E, Sastre J, Abad A, et al.  UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology. 1999;13:35–40
  22. Carmichael J, Popiela T, Radstone D, et al.  Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002;20:3617–3627
  23. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997;15:110–115
  24. Borner M, Schöffski P, de Wit R, et al.  A randomized crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2000;19:191a; (Abstract 741)
  25. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc. Sci. Med. 1992;35:1505–1509

☆ Sources of funding: Taiho Pharmaceutical Company, Japan; Bristol-Myers Squibb, New Jersey.

☆☆ For correspondence: Professor Douillard, Centre Rene Gauducheau, Site Hospitalier Nord, France. E-mail: jy-douillard@nantes.fnclcc.fr.

★ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(02)00125-1

doi: 10.1016/S0305-7372(02)00125-1

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 59-63 , February 2003

Article Tools